Arkolith/Insider Trading/MLTX/Form 4

Bodenstedt Matthias

Chief Financial OfficerMoonLake Immunotherapeutics (MLTX) · full profile →Form 4 · filed Dec 22, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 19, 2025Conversion(C)294K——922K
Dec 19, 2025Disposed to issuer(D)294K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 19, 2025Conversion(C)9K——0

Transaction Codes

C
Conversion of a derivative
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001213900-25-124519) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML